• Mac GroryBrianBDepartment of Neurology, Duke University School of Medicine, Durham, North Carolina.Duke Clinical Research Institute, Durham, North Carolina., DaJuanicia N Holmes, Roland A Matsouaka, Shreyansh Shah, ChangCherylee W JCWJDepartment of Neurology, Duke University School of Medicine, Durham, North Carolina., Richard Rison, Jenelle Jindal, Christine Holmstedt, William R Logan, Candy Corral, Jason S Mackey, Joey R Gee, David Bonovich, James Walker, Toby Gropen, Curtis Benesch, Jonathan Dissin, Hemant Pandey, David Wang, Martin Unverdorben, Adrian F Hernandez, Mathew Reeves, Eric E Smith, Lee H Schwamm, Deepak L Bhatt, Jeffrey L Saver, Gregg C Fonarow, Eric D Peterson, and Ying Xian.
• Department of Neurology, Duke University School of Medicine, Durham, North Carolina.
• JAMA. 2023 Jun 20; 329 (23): 203820492038-2049.

ImportanceUse of oral vitamin K antagonists (VKAs) may place patients undergoing endovascular thrombectomy (EVT) for acute ischemic stroke caused by large vessel occlusion at increased risk of complications.ObjectiveTo determine the association between recent use of a VKA and outcomes among patients selected to undergo EVT in clinical practice.Design, Setting, And ParticipantsRetrospective, observational cohort study based on the American Heart Association's Get With the Guidelines-Stroke Program between October 2015 and March 2020. From 594 participating hospitals in the US, 32 715 patients with acute ischemic stroke selected to undergo EVT within 6 hours of time last known to be well were included.ExposureVKA use within the 7 days prior to hospital arrival.Main Outcome And MeasuresThe primary end point was symptomatic intracranial hemorrhage (sICH). Secondary end points included life-threatening systemic hemorrhage, another serious complication, any complications of reperfusion therapy, in-hospital mortality, and in-hospital mortality or discharge to hospice.ResultsOf 32 715 patients (median age, 72 years; 50.7% female), 3087 (9.4%) had used a VKA (median international normalized ratio [INR], 1.5 [IQR, 1.2-1.9]) and 29 628 had not used a VKA prior to hospital presentation. Overall, prior VKA use was not significantly associated with an increased risk of sICH (211/3087 patients [6.8%] taking a VKA compared with 1904/29 628 patients [6.4%] not taking a VKA; adjusted odds ratio [OR], 1.12 [95% CI, 0.94-1.35]; adjusted risk difference, 0.69% [95% CI, -0.39% to 1.77%]). Among 830 patients taking a VKA with an INR greater than 1.7, sICH risk was significantly higher than in those not taking a VKA (8.3% vs 6.4%; adjusted OR, 1.88 [95% CI, 1.33-2.65]; adjusted risk difference, 4.03% [95% CI, 1.53%-6.53%]), while those with an INR of 1.7 or lower (n = 1585) had no significant difference in the risk of sICH (6.7% vs 6.4%; adjusted OR, 1.24 [95% CI, 0.87-1.76]; adjusted risk difference, 1.13% [95% CI, -0.79% to 3.04%]). Of 5 prespecified secondary end points, none showed a significant difference across VKA-exposed vs VKA-unexposed groups.Conclusions And RelevanceAmong patients with acute ischemic stroke selected to receive EVT, VKA use within the preceding 7 days was not associated with a significantly increased risk of sICH overall. However, recent VKA use with a presenting INR greater than 1.7 was associated with a significantly increased risk of sICH compared with no use of anticoagulants.

41 keywords...

hide…